AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11370993 — intervention group
Group type: COMPARATOR
Intervention: Placebo condition (TMS applied to the occipital cortex)
Number of subjects: 18
Study 9734883 — intervention group
Group type: EXPERIMENTAL
Intervention: Portal-vein infusion (PVI) of fluorouracil (500 mg/m2) plus heparin (5000 IU daily for 7 days)
Number of subjects: 1235
Study 9734883 — intervention group
Group type: COMPARATOR
Intervention: Control group (surgery alone)
Number of subjects: 1235
Study 9734883 — intervention group
Group type: EXPERIMENTAL
Intervention: Portal-vein infusion (PVI) of fluorouracil
Number of subjects: 1235
Study 8111606 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (16 mg/day)
Number of subjects: 29
Study 8111606 — intervention group
Group type: COMPARATOR
Intervention: Albuterol (800 micrograms/day)
Number of subjects: 29
Study 3416961 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous speech, music, or intermittent noise delivered to the left ear
Number of subjects: 0
Study 3416961 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent noise
Number of subjects: 0
Study 3416961 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous noise fed to the left ear
Number of subjects: 0
Study 31466923 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritual care program (three sessions conducted by a nurse, clergy, and patient's companion before, during, and after dressing change)
Number of subjects: 68
Study 31466923 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 68
Study 28209624 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 280
Study 28209624 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily
Number of subjects: 280
Study 28209624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 280
Study 26032655 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (LIRA) 1.2 mg QD s.c.
Number of subjects: 45
Study 26032655 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast (ROF) 500 mcg QD
Number of subjects: 45
Study 26032655 — intervention group
Group type: COMPARATOR
Intervention: Metformin (MET) 1000 mg BID
Number of subjects: 45
Study 23609792 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose combined with fat (0.5 g/kg body weight fructose, 1 g/kg OFTT cream as fat)
Number of subjects: 9
Study 23609792 — intervention group
Group type: COMPARATOR
Intervention: Fat only (1 g/kg OFTT cream)
Number of subjects: 9
Study 23609792 — intervention group
Group type: COMPARATOR
Intervention: Glucose (0.5 g/kg body weight)
Number of subjects: 9
Study 23609792 — intervention group
Group type: COMPARATOR
Intervention: Fructose (0.5 g/kg body weight)
Number of subjects: 9
Study 21746729 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-oxygen group (oxygen titration starting from 100%)
Number of subjects: 0
Study 21746729 — intervention group
Group type: COMPARATOR
Intervention: High-oxygen group (static concentration of 100% oxygen)
Number of subjects: 0
Study 21746729 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-oxygen group (starting from 21% oxygen)
Number of subjects: 0
Study 19166298 — intervention group
Group type: EXPERIMENTAL
Intervention: Purple carrot juice containing 76 micromol (65 mg) of total anthocyanins
Number of subjects: 10
Study 19166298 — intervention group
Group type: EXPERIMENTAL
Intervention: Purple carrot juice containing 228 micromol (194 mg) of total anthocyanins
Number of subjects: 10
Study 19166298 — intervention group
Group type: EXPERIMENTAL
Intervention: Purple carrot juice containing 380 micromol (323 mg) of total anthocyanins
Number of subjects: 10
Study 19166298 — intervention group
Group type: EXPERIMENTAL
Intervention: Acylated anthocyanins in purple carrot juice
Number of subjects: 10
Study 19166298 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonacylated anthocyanins in purple carrot juice
Number of subjects: 10
Study 16700404 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid multi-vitamin/mineral supplement
Number of subjects: 14
Study 16700404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 16146036 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser biostimulation
Number of subjects: 6
Study 16146036 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment only
Number of subjects: 6
Study 14559928 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplement containing 150 mg DHEA, 300 mg androstenedione, 750 mg Tribulus terrestris, 625 mg chrysin, 300 mg indole‐3‐carbinol, and 540 mg saw palmetto
Number of subjects: 100
Study 14559928 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplement containing DHEA, androstenedione and herbal extracts
Number of subjects: 100
Study 14559928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 11203865 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetric Ceram
Number of subjects: 6
Study 11203865 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji IX
Number of subjects: 6
Study 11203865 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophobic materials
Number of subjects: 6
Study 11203865 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic materials
Number of subjects: 6
Study 9256120 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial radiation (CRT) and intrathecal methotrexate (IT MTX)
Number of subjects: 192
Study 9256120 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended triple intrathecal therapy (TIT)
Number of subjects: 192
Study 1554839 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (≤2 g IM daily for at least 2 weeks)
Number of subjects: 18
Study 1554839 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline for 4 weeks plus streptomycin for 2 weeks
Number of subjects: 18
Study 3547993 — intervention group
Group type: EXPERIMENTAL
Intervention: OM-8930
Number of subjects: 64
Study 3547993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 30282375 — intervention group
Group type: EXPERIMENTAL
Intervention: Idebenone
Number of subjects: 64
Study 30282375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 26633582 — intervention group
Group type: EXPERIMENTAL
Intervention: Active gas aspiration
Number of subjects: 74
Study 26633582 — intervention group
Group type: COMPARATOR
Intervention: Simple gas evacuation (control)
Number of subjects: 74
Study 24977497 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive medical management
Number of subjects: 390
Study 24977497 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 390
Study 22268591 — intervention group
Group type: COMPARATOR
Intervention: Intranasal midazolam (0.2 mg·kg(‐1))
Number of subjects: 90
Study 22268591 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine (1 μg·kg(‐1))
Number of subjects: 90
Study 20038617 — intervention group
Group type: EXPERIMENTAL
Intervention: Amdoxovir (AMDX) at 500 mg b.i.d. + ZDV at 200 mg b.i.d.
Number of subjects: 24
Study 20038617 — intervention group
Group type: EXPERIMENTAL
Intervention: Amdoxovir (AMDX) at 500 mg b.i.d. + ZDV at 300 mg b.i.d.
Number of subjects: 24
Study 20038617 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine (ZDV) at 200 mg b.i.d.
Number of subjects: 24
Study 20038617 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine (ZDV) at 300 mg b.i.d.
Number of subjects: 24
Study 20038617 — intervention group
Group type: COMPARATOR
Intervention: Amdoxovir (AMDX) at 500 mg b.i.d. + placebo
Number of subjects: 24
Study 18686421 — intervention group
Group type: EXPERIMENTAL
Intervention: Different devices to measure temperature
Number of subjects: 0
Study 18686421 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 16408674 — intervention group
Group type: COMPARATOR
Intervention: Fixed combination timolol‐dorzolamide
Number of subjects: 38
Study 16408674 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost
Number of subjects: 38
Study 16408674 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 38
Study 12716811 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic reminder plus a letter summarizing the beneficial effects of antiplatelet drugs
Number of subjects: 15343
Study 12716811 — intervention group
Group type: COMPARATOR
Intervention: Control group received only the letter
Number of subjects: 15343
Study 10609972 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.56 g/kg alcohol
Number of subjects: 24
Study 10609972 — intervention group
Group type: COMPARATOR
Intervention: Alcohol placebo
Number of subjects: 24
Study 10609972 — intervention group
Group type: COMPARATOR
Intervention: Soda
Number of subjects: 24
Study 7581058 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg Loratadine daily for 3-4 days
Number of subjects: 6
Study 7581058 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 30 mg Loratadine
Number of subjects: 6
Study 7581058 — intervention group
Group type: COMPARATOR
Intervention: 10 mg Loratadine for 5 days
Number of subjects: 6
Study 2008985 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilator circuit changes every 48 hours (Group 1)
Number of subjects: 73
Study 2008985 — intervention group
Group type: COMPARATOR
Intervention: No change in ventilator circuits (Group 2)
Number of subjects: 73
Study 2008985 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups were similar in terms of age, indication for and duration of ventilation, and severity of illness.
Number of subjects: 73
Study 2008985 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilator-associated pneumonia defined by specific criteria
Number of subjects: 73
Study 2008985 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial colonization assessed every 48 hours
Number of subjects: 73
Study 6123332 — intervention group
Group type: EXPERIMENTAL
Intervention: Estazolam (2 mg)
Number of subjects: 10
Study 6123332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31666068 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic measurements in healthy subgroup
Number of subjects: 575
Study 31666068 — intervention group
Group type: COMPARATOR
Intervention: Echocardiographic measurements in general population
Number of subjects: 575
Study 31666068 — intervention group
Group type: EXPERIMENTAL
Intervention: M-mode derived LV measurements
Number of subjects: 575
Study 31666068 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricle basal dimension
Number of subjects: 575
Study 29020174 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 3949
Study 29020174 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI/ARB therapy
Number of subjects: 3949
Study 26194691 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OC)
Number of subjects: 90
Study 26194691 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin + Oral contraceptives (OC)
Number of subjects: 90
Study 26194691 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin alone
Number of subjects: 90
Study 26194691 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 90
Study 23592752 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.4 g/d EPA + DHA supplementation
Number of subjects: 26
Study 23592752 — intervention group
Group type: COMPARATOR
Intervention: 0.85 g/d EPA + DHA supplementation
Number of subjects: 26
Study 23592752 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 21916639 — intervention group
Group type: EXPERIMENTAL
Intervention: T12PR24 (telaprevir for 12 weeks, peginterferon-ribavirin for 24 weeks)
Number of subjects: 540
Study 21916639 — intervention group
Group type: EXPERIMENTAL
Intervention: T12PR48 (telaprevir for 12 weeks, peginterferon-ribavirin for 48 weeks)
Number of subjects: 540
Study 21916639 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (all patients)
Number of subjects: 540
Study 19567451 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Number of subjects: 306
Study 19567451 — intervention group
Group type: COMPARATOR
Intervention: LV5FUs
Number of subjects: 306
Study 17100745 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-welded titanium frameworks
Number of subjects: 155
Study 17100745 — intervention group
Group type: COMPARATOR
Intervention: Conventional gold alloy frameworks
Number of subjects: 155
Study 15289960 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA (8-10 mg/kg per day)
Number of subjects: 8
Study 15289960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 11786598 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Habits (HH)
Number of subjects: 44
Study 11786598 — intervention group
Group type: COMPARATOR
Intervention: Typical Care (TC)
Number of subjects: 44
Study 9675655 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural beta interferon 3,000,000 international units intramuscularly three times a week for 4 weeks
Number of subjects: 40
Study 9675655 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic drugs (control group)
Number of subjects: 40
Study 9675655 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural beta interferon
Number of subjects: 40
Study 8088691 — intervention group
Group type: EXPERIMENTAL
Intervention: nilvadipine 8 mg (mornings) and placebo (evenings)
Number of subjects: 61
Study 8088691 — intervention group
Group type: COMPARATOR
Intervention: slow‐release nifedipine 20 mg b.i.d.
Number of subjects: 61
Study 2654201 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based instructional system in pharmacokinetics
Number of subjects: 0
Study 2654201 — intervention group
Group type: COMPARATOR
Intervention: Conventional teaching in clinical pharmacokinetics
Number of subjects: 0
Study 1101616 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.375%
Number of subjects: 0
Study 1101616 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidocaine 0.5%
Number of subjects: 0
Study 1101616 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.5%
Number of subjects: 0
Study 1101616 — intervention group
Group type: COMPARATOR
Intervention: Etidocaine 0.375%
Number of subjects: 0
Study 6104497 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 0.25 mg ml-1 i.v. (average dose 0.014 mg kg-1)
Number of subjects: 82
Study 6104497 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 5 mg ml-1 i.v. (0.29 mg kg-1)
Number of subjects: 82
Study 6104497 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam
Number of subjects: 82
Study 6104497 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 82
Study 31619429 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy lifestyles program
Number of subjects: 30
Study 31619429 — intervention group
Group type: COMPARATOR
Intervention: Comparator arm
Number of subjects: 30
Study 29074420 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TXA)
Number of subjects: 149
Study 29074420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 26844764 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum albumin levels (mean 3.5 ± 0.5 g/dL)
Number of subjects: 456
Study 24637284 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexuality education coaching program (10 sessions over 3 weeks)
Number of subjects: 44
Study 24637284 — intervention group
Group type: COMPARATOR
Intervention: Control group received 2 sessions of sexuality education (including physiology and sexual abuse prevention)
Number of subjects: 44
Study 21262935 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbond XT (etch-and-rinse adhesive) with torsion load
Number of subjects: 60
Study 21262935 — intervention group
Group type: COMPARATOR
Intervention: Transbond XT (etch-and-rinse adhesive) without torsion load
Number of subjects: 60
Study 21262935 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbond Plus (self-etching primer adhesive) with torsion load
Number of subjects: 60
Study 21262935 — intervention group
Group type: COMPARATOR
Intervention: Transbond Plus (self-etching primer adhesive) without torsion load
Number of subjects: 60
Study 21262935 — intervention group
Group type: EXPERIMENTAL
Intervention: Beauty Ortho Bond (self-etching primer adhesive) with torsion load
Number of subjects: 60
Study 21262935 — intervention group
Group type: COMPARATOR
Intervention: Beauty Ortho Bond (self-etching primer adhesive) without torsion load
Number of subjects: 60
Study 21262935 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsion load (1.45 N/cm) applied
Number of subjects: 60
Study 21262935 — intervention group
Group type: COMPARATOR
Intervention: No torsion load applied
Number of subjects: 60
Study 19175870 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV FibroSURE
Number of subjects: 95
Study 19175870 — intervention group
Group type: EXPERIMENTAL
Intervention: FIBROSpect II
Number of subjects: 95
Study 17717768 — intervention group
Group type: EXPERIMENTAL
Intervention: DisCoVisc
Number of subjects: 35
Study 17717768 — intervention group
Group type: COMPARATOR
Intervention: Healon
Number of subjects: 35
Study 12944341 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole, 30 mg/day (reduced to 15 mg/day if needed for tolerability)
Number of subjects: 262
Study 12944341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 262
Study 12944341 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 262
Study 12944341 — intervention group
Group type: COMPARATOR
Intervention: Aripiprazole and Placebo
Number of subjects: 262
Study 10870361 — intervention group
Group type: EXPERIMENTAL
Intervention: Low doses of racemic ketamine
Number of subjects: 0
Study 10870361 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 0
Study 9369422 — intervention group
Group type: EXPERIMENTAL
Intervention: BCR/ABL-positive patients (n=23, 22% of total)
Number of subjects: 144
Study 9369422 — intervention group
Group type: COMPARATOR
Intervention: BCR/ABL-negative patients
Number of subjects: 144
Study 8239585 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 31
Study 8239585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 3519236 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide capsules (600 mg per day, q.i.d.)
Number of subjects: 14
Study 3519236 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide slow release tablets (600 mg per day, b.i.d.)
Number of subjects: 14
Study 3519236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 28850429 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy or manual therapy
Number of subjects: 181
Study 28850429 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 181
Study 25239466 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine at 200 mg twice daily
Number of subjects: 526
Study 25239466 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz at 600 mg daily
Number of subjects: 526
Study 23230122 — intervention group
Group type: EXPERIMENTAL
Intervention: PDEOC-10 diet (10% by-product)
Number of subjects: 60
Study 23230122 — intervention group
Group type: EXPERIMENTAL
Intervention: PDEOC-20 diet (20% by-product)
Number of subjects: 60
Study 23230122 — intervention group
Group type: COMPARATOR
Intervention: Control diet (PDEOC-0, without olive by-product)
Number of subjects: 60
Study 21712242 — intervention group
Group type: COMPARATOR
Intervention: Rifabutin 150 mg once daily
Number of subjects: 33
Study 21712242 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin 150 mg with atazanavir 300 mg/ritonavir 100 mg once daily
Number of subjects: 33
Study 21712242 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin 150 mg three times weekly with atazanavir/ritonavir
Number of subjects: 33
Study 19584189 — intervention group
Group type: COMPARATOR
Intervention: 1 mg estradiol combined with 2.5 mg medroxyprogesterone
Number of subjects: 11
Study 19584189 — intervention group
Group type: COMPARATOR
Intervention: 5 mg/d oral risedronate (Actonel)
Number of subjects: 11
Study 19584189 — intervention group
Group type: EXPERIMENTAL
Intervention: soy isoflavones from cotyledon
Number of subjects: 11
Study 19584189 — intervention group
Group type: EXPERIMENTAL
Intervention: soy isoflavones from germ
Number of subjects: 11
Study 17722825 — intervention group
Group type: EXPERIMENTAL
Intervention: Penetration needling combined with electroacupuncture
Number of subjects: 80
Study 17722825 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture combined with electroacupuncture
Number of subjects: 80
Study 14506078 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (Sandostatin LAR)
Number of subjects: 7
Study 11421500 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-killed Mycobacterium vaccae (M. vaccae)
Number of subjects: 337
Study 9394204 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive training methods in STD management at one health center.
Number of subjects: 400
Study 9394204 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training in STD management).
Number of subjects: 400
Study 7967425 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive therapy (IST) using anti-lymphocyte globulin (ALG), cyclosporin A (CSA), and G-CSF
Number of subjects: 0
Study 7967425 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation (BMT) from HLA-identical sibling
Number of subjects: 0
Study 7967425 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioning for BMT using ALG and cyclophosphamide
Number of subjects: 0
Study 7967425 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardisation and improvement of supportive therapy
Number of subjects: 0
Study 2890791 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol 0.5% ophthalmic solution
Number of subjects: 10
Study 2890791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30388045 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoropyrimidine plus bevacizumab followed by irinotecan at first progression (arm A)
Number of subjects: 421
Study 30388045 — intervention group
Group type: COMPARATOR
Intervention: Fluoropyrimidine plus irinotecan plus bevacizumab (arm B)
Number of subjects: 421
Study 28395753 — intervention group
Group type: EXPERIMENTAL
Intervention: Selamectin/sarolaner spot-on formulation (6.0 mg selamectin and 1.0 mg sarolaner per kg bodyweight)
Number of subjects: 30
Study 28395753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30